The Assessment Of Prednisone In Remission Trial (Tapir)

Brief Description Of Study

The purpose of this study is to collect information about 2 different recommended treatments for granulomatosis with polyangiitis (GPA, Wegener’s). We want to find out whether patients with GPA do better if they stay on a maintenance dose of 5 mg of prednisone or come off of prednisone after GPA is well-controlled. There are 5 study visits and patients will be in the study for no longer than 18 months. To join this study, patients must have a GPA diagnosis and be taking prednisone.

Detailed Study Description

Patients who are eligible may be enrolled when their daily dose of prednisone is between 5 mg and 20 mg. Everyone in this study will have their dose of prednisone decreased, unless they enter the study at 5 mg. Some patients will be randomized to decrease their prednisone to 0 mg, others to decrease or maintain their prednisone to 5 mg daily. Randomization means that the decision as to which option a person will receive is decided "by chance," not choice, like tossing a coin.  Patients will complete surveys, have physical exams, and information from their medical record will be collected.  This study is a project of the Vasculitis Clinical Research Consortium (VCRC), which is a network of investigators in major North American vasculitis centers.  The VCRC is funded through the National Institutes of Health as a Rare Diseases Clinical Research Network with the purpose of promoting research in vasculitis. 

Clinical Study Identifier: 01933724


Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: The Assessment of Prednisone In Remission Trial (TAPIR)
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.